Skip to main content

Table 4 Changes in Fasting Lipid Profile from Baseline to Week 12

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

  

Baseline

Week 12

Baseline to week 12

 

Lipid Lowering Therapy

Mean (SD)

Mean (SD)

Mean Change

SD

P-value

Total Cholesterol

No (n = 44)

183 (36.6)

180 (35.4)

-9.2

23.2

0.02

 

Yes (n = 18)

225 (64.3)

221 (55.1)

-2.9

44.3

0.80

 

Total population

195 (49.7)

191 (45.1)

-7.3

30.7

0.09

Triglycerides

No (n = 38)

178 (114)

153 (105)

-33.1

86.3

0.04

 

Yes (n = 16)

411 (392)

303 (281)

-81.2

348.3

0.40

 

Total population

246 (253)

194 (182)

-47.4

199.9

0.11

HDL

No (n = 37)

45.3 (11.6)

44.6 (13.7)

-4.5

9.4

0.01

 

Yes (n = 17)

36.1 (15.5)

39.1 (17.2)

1.7

9.5

0.49

 

Total population

42.4 (13.5)

43.0 (14.8)

-2.5

9.8

0.88

LDL

No (n = 38)

106 (28.0)

105 (25.9)

-4.2

21.8

0.28

 

Yes (n = 16)

127 (54.9)

125 (36.1)

3.6

48.6

0.79

 

Total population

112 (38.7)

110 (30.2)

-1.9

31.8

0.69

  1. HDL = high density lipoprotein; LDL = low density lipoprotein; SD = standard deviation